Lv51
810 积分 2024-07-08 加入
Heterogeneity and treatment landscape of ovarian carcinoma
3个月前
已完结
Precursors and pathogenesis of ovarian carcinoma
6个月前
已完结
Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments
6个月前
已完结
Exploiting bacteria for cancer immunotherapy
7个月前
已完结
Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization
7个月前
已完结
Clinical and translational advances in ovarian cancer therapy
9个月前
已完结
GPR183及其在相关疾病中的免疫调控作用
9个月前
已完结
Clinical and translational advances in ovarian cancer therapy
1年前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
1年前
已完结
皖公网安备34019202002308
